Evidence map›Paper›PMID 39206099›Full record

ArticleRespiratory medicine case reports2024

Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung.

Antoine El Kik, Maarten Vander Kuylen, Benjamin Bailly, Jennifer Fallas, Benjamin Bondue

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Clinical case reports · 2026
    Article
  2. Article
  3. Pseudotumoral PulmonaryDiagnostics (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Antoine El KikDepartment of Pneumology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Maarten Vander KuylenDepartment of Thoracic Surgery, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Benjamin BaillyDepartment of Hematology, Hôpital de La Louvière - Site Jolimont, Haine-Saint-Paul, Belgium.
Jennifer FallasDepartment of Pathology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Benjamin BondueDepartment of Pneumology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although pulmonary complications are frequent in patients suffering from hematological diseases, secondary pulmonary alveolar proteinosis is a very rare complication of myelofibrosis. We describe the case of a 65-year-old male patient treated by Ruxolitinib for myelofibrosis who developed a secondary pulmonary alveolar proteinosis complicated by a

Indexed as

Mycobacterium aviumMyelofibrosisPulmonary alveolar proteinosisRuxolitinib

Identifiers

PMID39206099
PMCPMC11350458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.